Entity Wide Disclosures

9 Months Ended

Sep. 30, 2019

Entity Wide Disclosures [Abstract]

Entity Wide Disclosures

(14) Entity Wide Disclosures

Revenue by Category

The following table disaggregates our revenue by major source (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Therapeutic Area
Oncology	$	65,529	$	48,947	$	186,152	$	135,824
Other		53,484		42,200		158,676		114,852
Metabolic		34,919		30,037		102,287		90,748
AVAI		24,243		21,947		66,831		59,497
Cardiology		21,733		22,227		68,792		71,262
Central Nervous System		16,330		13,895		48,345		40,291
Total revenue	$	216,238	$	179,253	$	631,083	$	512,474

In the current quarter and for all periods presented, the revenue associated with medical device projects, previously a separate therapeutic area, has been included in the respective therapeutic area that best aligns with the therapeutic focus of the medical device project and represents how management evaluates disaggregated revenue in its internal reporting.